A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Jun 2018 This trial has accrued 5 patients and enrollment will complete in 12 months, as reported in an abstract presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 26 Apr 2018 According to an Exelixis media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.